Physician profile
Bret Rogers
NPI 1922123744
$4,615.77
in general payments reported to CMS, 2019-2025
23 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,472 · 2020: $342 · 2021: $99.49 · 2022: $1,594 · 2023: $480 · 2024: $385 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,244.87 | 2019-2025 | Mitraclip |
| Novartis Pharmaceuticals Corporation | $274.01 | 2019-2024 | |
| Boston Scientific Corporation | $212.61 | 2019-2023 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $212.47 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.34 | 2019-2024 | Jardiance |
| Inspire Medical Systems, INC. | $212.26 | 2022 | |
| Janssen Pharmaceuticals, INC | $188.70 | 2019-2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $183.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $135.35 | 2019-2024 | Camzyos |
| Abiomed | $132.27 | 2020 | |
| Scpharmaceuticals INC. | $115.20 | 2025 | |
| Pfizer INC. | $87.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $81.48 | 2019 | |
| Amgen INC. | $61.41 | 2019-2021 | |
| Akcea Therapeutics, INC. | $40.91 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $39.58 | 2019 | |
| Lundbeck LLC | $37.39 | 2019 | |
| Impulse Dynamics (USA) INC. | $36.02 | 2021 | |
| Amarin Pharma, INC. | $35.20 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $28.88 | 2024 | Opsumit |
| Astrazeneca Pharmaceuticals LP | $16.67 | 2019 | |
| Lantheus Medical Imaging, INC. | $15.88 | 2019 | |
| Philips North America LLC | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bret Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.